Clexane, known generically as enoxaparin sodium, is a low molecular weight heparin (LMWH) anticoagulant widely used in the prevention and treatment of thromboembolic disorders. As a cornerstone of modern antithrombotic therapy, it represents a significant advancement over unfractionated heparin (UFH), offering more predictable pharmacokinetics, easier administration, and a potentially improved safety profile. This report details its mechanism of action, key clinical indications, dosing regimens, and important safety considerations.

1. Chemical and rache.es - Pharmacological Profile
Enoxaparin is derived from UFH through controlled chemical or enzymatic depolymerization, resulting in shorter polysaccharide chains with a mean molecular weight of approximately 4500 daltons. Its primary mechanism of action is the potentiation of antithrombin III (ATIII), a natural inhibitor of coagulation factors. While both UFH and enoxaparin catalyze the inhibition of Factor Xa and Factor IIa (thrombin), enoxaparin exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity (approximately 3.8:1). This preferential inhibition of Factor Xa, which sits earlier in the coagulation cascade, allows for effective suppression of thrombus formation with a more predictable dose-response relationship and less effect on global clotting tests like the aPTT compared to UFH.

2. Primary Clinical Indications
Clexane is approved for a range of prophylactic and therapeutic uses:
Prophylaxis of Venous Thromboembolism (VTE): It is extensively used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in high-risk patients, including those undergoing major orthopedic surgery (total hip/knee replacement, hip fracture), general abdominal surgery, and medically ill patients at risk due to restricted mobility.
Treatment of Established VTE: It is indicated for the acute treatment of DVT with or without PE, often in conjunction with warfarin or a direct oral anticoagulant (DOAC) until the oral agent becomes therapeutic.
Unstable Angina and Non-ST-Elevation Myocardial Infarction (NSTEMI): Used in the management of acute coronary syndromes (ACS) in combination with antiplatelet agents like aspirin and/or clopidogrel to prevent ischemic complications.
ST-Elevation Myocardial Infarction (STEMI): Employed in conjunction with thrombolytic therapy or in patients undergoing percutaneous coronary intervention (PCI).
Extracorporeal Circulation: Used as an anticoagulant during hemodialysis in patients with renal failure.

3. Dosage and Administration
Clexane is administered exclusively via subcutaneous injection, typically into the abdominal wall. Intravenous administration is reserved for specific ACS protocols. Dosage is strictly weight-based and indication-specific, eliminating the need for routine monitoring of coagulation parameters in most patients. For example:
Surgical VTE Prophylaxis: Commonly 40 mg once daily or 30 mg twice daily.
Medical VTE Prophylaxis: 40 mg once daily.
Treatment of DVT/PE: 1 mg/kg every 12 hours or 1.5 mg/kg once daily.
ACS: 1 mg/kg every 12 hours administered alongside antiplatelet therapy.
Dosage adjustments are critical in patients with severe renal impairment (creatinine clearance <30 mL/min) due to renal excretion of the drug.

4. Advantages Over Unfractionated Heparin
The clinical preference for Clexane in many settings stems from several key advantages:
Predictable Pharmacokinetics: Due to better bioavailability and a longer half-life, it produces a reliable anticoagulant effect with fixed, weight-based dosing.
Simplified Administration: The subcutaneous route and once- or twice-daily dosing facilitate outpatient treatment (e.g., for DVT) and reduce nursing workload.
Reduced Monitoring: Does not require routine monitoring of aPTT, though periodic assessment of platelet counts is mandatory.
Potentially Lower Risk of HIT: The incidence of heparin-induced thrombocytopenia (HIT), a serious immune-mediated complication, is lower with LMWHs like enoxaparin compared to UFH.
Possible Reduced Bleeding Risk: Some meta-analyses suggest a marginally lower risk of major bleeding compared to UFH.

5. Adverse Effects and Safety Warnings
Despite its advantages, Clexane carries significant risks that necessitate careful patient selection and vigilance.
Bleeding: The most common and serious adverse effect. Risk factors include concomitant use of other anticoagulants or antiplatelets, advanced age, renal impairment, and low body weight. There is no specific antidote; protamine sulfate only partially reverses its anti-Factor IIa activity.
Heparin-Induced Thrombocytopenia (HIT): Although less frequent, HIT remains a critical concern. It involves a paradoxical drop in platelet count associated with a high risk of new thrombosis. Platelet count monitoring is recommended during therapy.
Spinal/Epidural Hematoma: A rare but catastrophic complication in patients receiving enoxaparin around the time of neuraxial anesthesia or spinal puncture, which can lead to permanent paralysis. Strict guidelines govern the timing of dose administration relative to the procedure.
Osteoporosis: With long-term use (months), there is a risk of bone mineral density loss and vertebral fractures.

• Other: Mild local reactions at the injection site, elevated liver enzymes, and rare cases of hyperkalemia due to suppressed aldosterone secretion.
  
  

Clexane is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin, heparin, or pork products, and in those with a history of HIT. Extreme caution is required in patients with a high risk of bleeding (e.g., peptic ulcer, hemorrhagic stroke, recent brain/spinal/eye surgery), uncontrolled hypertension, or severe renal/liver disease.
Significant drug interactions occur with agents that increase bleeding risk: other anticoagulants (warfarin, DOACs), antiplatelet drugs (aspirin, clopidogrel, NSAIDs), and thrombolytics (alteplase). Concurrent use requires meticulous benefit-risk assessment.

7. Monitoring and Special Populations
Routine coagulation monitoring (PT/aPTT) is not useful. In specific situations—such as pregnancy, extreme body weight, or renal failure—monitoring of anti-Factor Xa activity may be considered. Use in pregnancy (Category B) is relatively common for treating or preventing VTE, as it does not cross the placenta. It is secreted in breast milk in small amounts but is considered compatible with breastfeeding. Elderly patients often have age-related renal decline, necessitating dose evaluation.

Conclusion
Clexane (enoxaparin sodium) is a pivotal LMWH that has streamlined and improved antithrombotic management across multiple clinical domains. Its predictable effect, simplified dosing, and proven efficacy in VTE and ACS have made it a first-line agent. However, its use demands respect for its potent anticoagulant effect, with bleeding as the paramount risk. Clinicians must adhere to indication-specific, weight-based dosing protocols, remain vigilant for signs of HIT and bleeding, and carefully consider contraindications and interactions to optimize patient outcomes and safety.